List of investigational anxiolytics
This is a list of investigational anxiolytics, or anxiolytics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This list was last comprehensively updated in June 2017. It is likely to become outdated with time.
Generalized anxiety disorder
[edit]- Riluzole sublingual (BHV-0223) – undefined mechanism of action[1]
- TGFK08AA – 5-HT1A receptor modulator[2]
- TGW00AA (FKW00GA) – 5-HT1A receptor agonist, 5-HT2A receptor antagonist [3]
Panic disorder
[edit]- Darigabat (PF-06372865) – GABAA receptor positive allosteric modulator[4]
- Tebideutorexant (JNJ-61393215, JNJ-3215) – orexin OX1 receptor antagonist[5]
Post-traumatic stress disorder
[edit]- 7-Oxoprasterone (7-keto-DHEA; HBL-9001) – "immunomodulator" / undefined mechanism of action [6]
- BNC-210 (IW-2143) – "GABA modulator"[7] / undefined mechanism of action[8][9]
- Brexpiprazole (Lu AF41156, OPC-34712; Rexulti) – atypical antipsychotic / 5-HT1A, D2 and D3 receptor partial agonist and 5-HT2A, 5-HT2B, 5-HT7, α1-adrenergic, α2-adrenergic, and H1 receptor antagonist [10]
- Iloperidone (HP-873, ILO-522; Fanapt, Fiapta, Zomaril) – atypical antipsychotic / 5-HT2A, 5-HT6, 5-HT7, D2, D3, D4, and α1-adrenergic receptor antagonist [11]
- MDMA (Midomafetamine, 3,4-methylenedioxymethamphetamine, "ecstasy") – serotonin–norepinephrine–dopamine releasing agent and 5-HT1 and 5-HT2 receptor agonist – specifically under development as an aid to psychotherapy for post-traumatic stress disorder [12][13][14]
- NBTX-001 (Xenon) – NMDA receptor antagonist [15]
- Pomaglumetad methionil (DB-103, LY-2140023) – mGluR2 and mGluR3 agonist [16]
- Tianeptine oxalate/naloxone (TNX-601) – atypical μ-opioid receptor agonist [17]
Social anxiety disorder
[edit]- Fasedienol (Aloradine; PH94B; 4-androstadienol) – vomeropherine / neurosteroid[18]
- JNJ-42165279 – FAAH inhibitor[19][20]
- TGW00AA (FKW00GA) – 5-HT1A receptor agonist, 5-HT2A receptor antagonist [3]
Others/unspecified
[edit]- BNC-210 (IW-2143) – "GABA modulator"[7] / undefined mechanism of action / α7 subunit-containing nicotinic acetylcholine receptor antagonist[8][9]
- Deuterated etifoxine (GRX-917) – translocator protein (TSPO) agonist and GABAA receptor positive allosteric modulator[21][22]
- JNJ-42165279 – FAAH inhibitor[23]
- JNJ-61393215 – orexin OX1 receptor antagonist [5]
- Maritupirdine (AVN-101; Aviandr) – 5-HT6 receptor antagonist [24]
- MP-20X – CB1 and 5-HT1A receptor modulator [25]
- SRX-246 – vasopressin V1A receptor antagonist [26]
See also
[edit]References
[edit]- ^ "Riluzole sublingual - Biohaven Pharmaceuticals - AdisInsight". adisinsight.springer.com.
- ^ "TGFK 08AA - AdisInsight". adisinsight.springer.com.
- ^ a b "FKW 00GA - AdisInsight". adisinsight.springer.com.
- ^ "Darigabat - Cerevel Therapeutics - AdisInsight". adisinsight.springer.com.
- ^ a b "JNJ 61393215 - AdisInsight". adisinsight.springer.com.
- ^ "7-Oxoprasterone - Humanetics - AdisInsight". adisinsight.springer.com. Archived from the original on 2017-10-22.
- ^ a b Garakani A, Murrough JW, Iosifescu DV (2014). "Advances in Psychopharmacology for Anxiety Disorders". FOCUS. 12 (2): 152–162. doi:10.1176/appi.focus.12.2.152. ISSN 1541-4094.
- ^ a b Doggrell, S. A. (2007). Novel drugs and products in neuroscience. Drugs of the Future, 32(11), 1007-1017. https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3853&p_IsPs=Y
- ^ a b "BNC 210 - AdisInsight". adisinsight.springer.com.
- ^ "Brexpiprazole - Lundbeck/Otsuka - AdisInsight". adisinsight.springer.com.
- ^ "Iloperidone - Vanda Pharmaceuticals - AdisInsight". adisinsight.springer.com.
- ^ "Methylenedioxymetamfetamine - MAPS Europe B.V. - AdisInsight". adisinsight.springer.com.
- ^ Sessa B (2017). "MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics"". Neurosci. Lett. 649: 176–180. doi:10.1016/j.neulet.2016.07.004. PMID 27394687. S2CID 3803704.
- ^ Philipps D (29 November 2016). "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients". The New York Times. Retrieved 1 June 2017.
- ^ "NBTX 001 - AdisInsight". adisinsight.springer.com.
- ^ "Pomaglumetad methionil - Denovo Biopharma/Eli Lilly and Company - AdisInsight". adisinsight.springer.com.
- ^ "Naloxone/tianeptine - Tonix Pharmaceuticals - AdisInsight". adisinsight.springer.com.
- ^ "Fasedienol - Pherin Pharmaceuticals/VistaGen Therapeutics - AdisInsight". adisinsight.springer.com.
- ^ "JNJ 42165279 - AdisInsight". adisinsight.springer.com. Retrieved 2019-03-02.
- ^ "A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder | Clinical Research Trial Listing ( Claustrophobia ) ( NCT02432703 )". www.centerwatch.com. Retrieved 2019-03-02.
- ^ "Etifoxine deuterated - GABA Therapeutics - AdisInsight". adisinsight.springer.com.
- ^ Rupprecht R, Pradhan AK, Kufner M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Puig X, Rupprecht C, Rammes G (December 2022). "Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options". Eur Arch Psychiatry Clin Neurosci. 273 (7): 1477–1487. doi:10.1007/s00406-022-01532-3. PMID 36574032. S2CID 255205221.
- ^ "JNJ 42165279 - AdisInsight". adisinsight.springer.com.
- ^ "AVN 101 - AdisInsight". adisinsight.springer.com.
- ^ "Medipure Pharmaceutical MP-20X product line for anxiety". medipurepharmaceuticals. Archived from the original on 2016-10-29.
- ^ "SRX 246 - AdisInsight". adisinsight.springer.com.